Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 20/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16461931 | 0.81 | P2RX7 (0.56) | P2RX7 | |
| SCHEMBL16462817 | 0.79 | P2RX7 (0.47) | P2RX7 | |
| SCHEMBL16462958 | 0.79 | P2RX7 (0.48) | P2RX7 | |
| SCHEMBL16465916 | 0.78 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL16461778 | 0.75 | P2RX7 (0.51) | P2RX7 | |
| SCHEMBL16462049 | 0.74 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL16462789 | 0.74 | P2RX7 (0.49) | P2RX7 | |
| SCHEMBL16463056 | 0.73 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL16462121 | 0.73 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL16462565 | 0.72 | P2RX7 (0.38) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | MINDIMMUNE THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | MINDIMMUNE THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2906546-B1 | BENZAMIDES | H LUNDBECK AS (DK) | 2018-01-10 | — | — | EP | disclosed |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | H. LUNDBECK A/S (DK) | 2017-07-20 | — | — | US | disclosed |
| US-9649308-B2 | Benzamide-containing compounds and their use in the treatment of pain | H. LUNDBECK A/S (DK) | 2017-05-16 | — | — | US | disclosed |
| US-20150283134-A1 | Benzamides | MINDIMMUNE THERAPEUTICS, INC. | 2015-10-08 | — | — | US | disclosed |
| EP-2906546-A1 | BENZAMIDES | H. Lundbeck A/S (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-9102591-B2 | Benzamides | H. LUNDBECK A/S (DK) | 2015-08-11 | — | — | US | disclosed |
| WO-2014057078-A1 | BENZAMIDES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
| US-20140107340-A1 | Benzamides | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054630-A1 | BENZAMIDES-CONTAINING COMPOUNDS AND THEIR USE IN THE TREATMENT OF DEPRESSION | P2RX5, P2RX7, P2RX2 | P2RX7 2/4885 |
| US-20140107340-A1 | Benzamides | P2RX7, TRPV1, P2RX5 | P2RX7 1/4885 |
| US-10238654-B2 | Benzamides-containing compounds and their use in the treatment of epilepsy | P2RX5, P2RX7, P2RX6 | P2RX7 2/4885 |
| US-20170202836-A1 | Benzamides-Containing Compounds and Their Use in the Treatment of Epilepsy | P2RX5, P2RX7, P2RX6 | P2RX7 2/4885 |
| US-20150283134-A1 | Benzamides | P2RX7, TRPV1, P2RX5 | P2RX7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.